BEF, Author at The Boomer Esiason Foundation

March 19, 2019

via Cystic Fibrosis News Today Aptalis Pharma continued to evaluate its pancreatic enzyme products (PEPs) in patients with cystic fibrosis and exocrine pancreatic insufficiency in its Phase 4 clinical trial of Panzytrat® 25,000. Results show that patients taking Panzytrat had better control over their steatorrhea, or...

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

Via Cystic Fibrosis News Today After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004, the cost and availability of the products added another hardship to the lives of cystic fibrosis patients, some of whom use PEPs to...

IFN-γ Found to Help Clear Lethal Bacteria in Cystic Fibrosis Infections via Bio News -TX

by BEF

CF News, Research, Therapies

March 19, 2019

SOURCE - BIO NEWS TEXAS Researchers at The Research Institute at Nationwide Children’s Hospital in Ohio are finding ways to boost immunity in cystic fibrosis patients. Colleagues in principal investigator Dr. Benjamin Kopp’s laboratory published a study in PLoS One that details the use of interferon...

Alcresta Announces Agreement with CFF Therapeutics to Develop Point-of-Care Nutritional Products

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE - Marketwatch.com PRESS RELEASE April 17, 2014, 7:31 a.m. EDT Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products Agreement Highlights Importance of Medical Nutrition in Managing Cystic Fibrosis NEWTON, Mass., Apr 17, 2014 (BUSINESS WIRE) -- Alcresta®, a leading medical nutrition company developing innovative...

Attention CF Patients with Persistent MRSA Lung Infection

by BEF

CF Community, CF News, Research

March 19, 2019

Attention CF Patients With Persistent MRSA Lung Infection: A Phase 2 clinical trial to evaluate the safety and efficacy of an inhaled anti-MRSA antibiotic is enrolling now. MRSA + CF The prevalence of MRSA lung infection in cystic fibrosis (CF) patients has risen in the past decade, currently...

Kamada Ltd. Launching New CF Clinical Trial this Summer

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE [Posted by Mike Nace on bionews-tx.com] Israel-based Kamada Ltd., a drug development company currently developing plasma-derived protein therapeutics that are chiefly targeting orphan diseases, indicated recently in a press release that their lead drug candidate Alpha-1 Antitrypsin (AAT), which is currently in trials for treatment of...

Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements

by BEF

CF Community, CF News, Research

March 19, 2019

SOURCE: Bionews-Tx.com Gentamicin belongs to the amino glycoside class of antibiotics and is used to treat mostly gram negative bacterial infections, including severe ones like pyelonephritis, biliary sepsis, endocarditis, and cystic fibrosis among others. It is a bactericidal antibiotic that binds irreversibly to the 30s subunit...

CFF Therapeutics Extends Drug Development Collaboration via CFF.org

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE: CFF.org Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508. Proteostasis will continue to focus...

U.S. FDA Approves KALYDECO™ for Use in Eight Additional CF Mutations

by BEF

CF News, Research, Therapies

March 19, 2019

SOURCE - VERTEX PRESS RELEASE KALYDECO is the first medicine to treat the underlying cause of CF for people with specific mutations in the CFTR gene KALYDECO facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein The eight additional mutations are present in...

Scientists Pinpoint 105 Additional Genetic Errors that Cause CF

by BEF

CF News, Research

March 19, 2019

SOURCE: CF Roundtable Of the over 1,900 errors already reported in the gene responsible for cystic fibrosis (CF), it is unclear how many of them actually contribute to the inherited disease. Now a team of researchers reports significant headway in figuring out which mutations are benign...

Author: BEF

Aptalis Pharma Studies Panzytrat in Cystic Fibrosis Patients in Phase 4 Trial via CF News Today

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption via CF News Today

IFN-γ Found to Help Clear Lethal Bacteria in Cystic Fibrosis Infections via Bio News -TX

Alcresta Announces Agreement with CFF Therapeutics to Develop Point-of-Care Nutritional Products

Attention CF Patients with Persistent MRSA Lung Infection

Kamada Ltd. Launching New CF Clinical Trial this Summer

Hearing Loss From Popular Cystic Fibrosis Antibiotic Could Be Treated With Vitamin Supplements

CFF Therapeutics Extends Drug Development Collaboration via CFF.org

U.S. FDA Approves KALYDECO™ for Use in Eight Additional CF Mutations

Scientists Pinpoint 105 Additional Genetic Errors that Cause CF

Never miss an update. Subscribe to our emails!